Precision Adjuvant Therapy Based on Detailed Pathologic Risk Factors for Resected Oral Cavity Squamous Cell Carcinoma: Long-Term Outcome Comparison of CGMH and NCCN Guidelines

Postoperative Radiotherapy Improved Survival in pT1-2N1 Oral and Oropharyngeal Cancer Without Adequate Neck Dissection ​

“…In contrast to the latest NCCN guidelines which suggest adjuvant radiotherapy for patients with pN1 disease, our results demonstrated that postoperative radiotherapy was effective only in those without good-quality neck dissection (LN yield < 18). 14,15 The protective effect of adjuvant radiotherapy failed to reach statistical signi cance for those with LN yield > 18. Because of the protective role of postoperative radiotherapy in oral and oropharyngeal cancer patients with pT1-2N1M0 disease without good-quality neck dissection, the NCCN guidelines for adjuvant radiotherapy in pN1 disease without adverse features may need to be modi ed according to the quality of retrieved LNs.…”

Prognostic significance of the preoperative systemic immune‐inflammation index in patients with oral cavity squamous cell carcinoma treated with curative surgery and adjuvant therapy

“…Patients harboring two minor risk factors or pN1 at level IV−V were given postoperative RT alone. The radiation dose per fraction was 2 Gray (Gy)––with the total dose being 60−66 Gy for adjuvant postoperative RT and 66 Gy for CCRT 15 . Dose escalation up to 70−72 Gy was allowed for patients who had evidence of early locoregional recurrence confirmed on biopsy or PET/CT imaging before adjuvant treatment.…”

Association between multidisciplinary team care and the completion of treatment for oral squamous cell carcinoma: A cohort population‐based study

“…The MDTC approach is proven effective for managing treatment for a variety of cancers. Studies show that MDTC can optimise a complex care plan (Badran et al, 2018), promote treatment compliance (Chang et al, 2020;Kelly et al, 2013;Liao et al, 2016;Rosell et al, 2018), enhance the quality of life post-treatment (Stephens et al, 2006) and prolong survival (Forrest et al, 2005;Liao et al, 2016). In European countries, the MDTC approach is standard for cancer care and required for cancer centre accreditation by the Organization of European Cancer Institutes (European Partnership Action Against Cancer Consensus Group et al, 2014).…”

“…Although previous cancer-related studies have explored this issue, most research has focused on HNC (Badran et al, 2018;Chang et al, 2020;Kelly et al, 2013), oesophageal cancer (Stephens et al, 2006), lung cancer (Forrest et al, 2005), health professionals (Rosell et al, 2018), quality of life (Stephens et al, 2006) and survival (Forrest et al, 2005;Liao et al, 2016). OSCC patients face much suffering, including psychological effects and disease burden, which may affect treatment decisions.…”

“…Checklist of reasons for failure to complete treatmentThe checklist used to gather patient information regarding reasons for failure to complete was based on interviews with patients who had terminated treatment before completion, previous studies(Chang et al, 2020;Chiang et al, 2018), patient medical records and expert opinions. The checklist contained 7 items: (1) Poor physical condition (chronic disease or uncontrolled systemic disease), difficulty enduring physical discomfort caused by treatment; (2) Patient, family or friends experienced negative treatment effects and worried about treatment side effects; (3) Transportation inconvenient; (4) Death; (5) Primary physician determined that the patient's physical condition precluded active treatment; (6) Poor familial support; and (7) Suicidal intentions.…”